Management of Hypertension in Patients with Chronic Kidney Disease and Diabetes Mellitus

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Treatment of patients at high risk for developing cardiovascular disease aims at controlling blood pressure, optimizing blood glucose levels, and providing renoprotection. Chronic kidney disease (CKD) and diabetes mellitus are prevalent causes of cardiovascular disease owing to associations with major cardiovascular risk factors, such as hypertension, and they are substantial health burdens. Even mild-to-moderate CKD and prehypertension increase cardiovascular risk. First-line agents for reducing cardiovascular risk are inhibitors of the renin-angiotensin system: angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). In clinical trials, treatment of high-risk patients with ACE inhibitors and ARBs delays or prevents the onset of diabetes and prevents progression of renal disease and cardiovascular events, including cardiovascular mortality. Current evidence indicates that the clinical efficacy of these end points includes effects that may be beyond blood pressure reduction.

Original languageEnglish (US)
Pages (from-to)S16-S22
JournalAmerican Journal of Medicine
Issue number8 SUPPL. 1
StatePublished - Aug 1 2008


  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Blood pressure
  • High cardiovascular risk
  • Hypertension
  • Renoprotection

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Management of Hypertension in Patients with Chronic Kidney Disease and Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this